Epithalon


Overview

Epithalon (Epitalon) is a tetrapeptide — just four amino acids — synthesized by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the flagship of Russian bioregulator peptide research and one of the most famous longevity peptides in the world.

The claim: it reactivates telomerase, the enzyme that rebuilds telomeres, potentially slowing cellular aging. The catch: nearly all research comes from one research group.

How It Works

Epithalon is based on epithalamin, a pineal gland extract. It appears to upregulate telomerase activity in human somatic cells — demonstrated in cell culture — and to modulate melatonin production and circadian regulation through its pineal effects.

The telomere story

Telomeres shorten with each cell division; when they run out, the cell dies or becomes senescent. Reactivating telomerase could theoretically extend cellular lifespan. Khavinson group studies in animals and small human cohorts report improved melatonin rhythms, retinal function and even mortality signals — but independent replication is essentially absent.

Key Benefits

Telomerase activation — demonstrated in vitro; the core longevity rationale.

Sleep and circadian normalization — the most plausible near-term effect via pineal modulation.

Antioxidant effects — reported in the Russian literature.

Longevity signals — animal lifespan extension and a small long-term human cohort study, all from the originating institute.

Side Effects & Considerations

Reported side effects are minimal — the peptide is a tiny fragment with low biological drama. The real consideration is epistemic: when one laboratory produces essentially all positive evidence for a compound over decades, skepticism is warranted until independent groups replicate.

The telomerase paradox

Telomerase reactivation is a double-edged sword — cancer cells immortalize themselves exactly this way. Whether intermittent, low-level telomerase modulation raises cancer risk is unknown. Standard community practice is short, infrequent cycles (10-20 days, a few times per year) partly for this reason. Not approved for human use outside Russia.

Dosage protocols

Protocol Dosage Frequency Duration Notes
Standard cycle (anecdotal) 5-10 mg Once daily 10-20 days, 2-3 times per year Short infrequent cycles are the community standard, partly from theoretical cancer caution.

Warnings

Evidence base comes almost entirely from one research institute. Theoretical cancer concern with telomerase activation. Not approved for human use.